Etanercept for the treatment of axial spondyloarthritis
I-H Song, Joachim Sieper · Clinical Investigation · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2013
Abstract
The introduction of etanercept (ETN; Enbrel®), and other TNF-blockers, has revolutionized the treatment of patients with ankylosing spondylitis. ETN, as with other approved TNF-blockers, shows good efficacy in treating spinal disease, especially if patients are treated early. Furthermore, studies involving ETN demonstrate good long-term efficacy.
This review summarizes the data on ETN in the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis, and discusses topics such as its efficacy in treating extra-articular manifestations, dose modifications and immunogenicity of ETN, and switching between ETN and other TNF-blockers, as well as radiographic progression and safety.
Open the resolved locator · 10.4155/cli.13.17
Metadata licence: OpenAlex metadata (CC0)